Yvan Le Bruchec

Adjuvant <i>nab</i> -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

Margaret A. Tempero, Uwe Pelzer, Eileen M. O’Reilly et al. · Journal of Clinical Oncology · 2022 · 132 citations · Full text

Medicine, Oncology, Pharmacology +13

Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study

Mark M. Awad, Yvan Le Bruchec, Brian Lu et al. · Frontiers in Oncology · 2021 · 47 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer

Lucas Moreno, Michela Casanova, Julia Chisholm et al. · European Journal of Cancer · 2018 · 32 citations · Full text

Medicine, Oncology, Pharmacology +14

Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network

Loredana Amoroso, Victoria Castel, Gianni Bisogno et al. · European Journal of Cancer · 2020 · 20 citations

Medicine, Oncology, Pharmacology +16